RS
HRTX icon

R Squared’s Heron Therapeutics HRTX Stock Holding History

R Squared’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.9K Buy
46,708
+13,093
+39% +$10.5K 0.01% 491
2026
Q1 		$26.9K Buy
+33,615
New +$39K 0.01% 450
2025
Q4 		– Sell
-15,219
Closed -$19.2K – 613
2025
Q3 		$19.2K Buy
15,219
+2,571
+20% +$4.08K 0.01% 529
2025
Q2 		$26.2K Buy
+12,648
New +$25.8K 0.01% 432
2025
Q1 		– Sell
-990
Closed -$1.51K – 827
2024
Q4 		$1.51K Buy
+990
New +$1.6K ﹤0.01% 1489

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

R Squared's HRTX Position: Q2 2026 in Review

R Squared increased its Heron Therapeutics (HRTX) stake by 39% in Q2 2026, buying an estimated $10.5K and bringing the position to 46,708 shares worth $19.9K. The position accounts for 0.01% of the portfolio, ranked #491.

R Squared first reported a position in HRTX in Q4 2024 and has held it in 5 quarters since. The position peaked at $26.9K in Q1 2026. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • R Squared held 46,708 shares of Heron Therapeutics worth $19.9K as of Q2 2026.
  • R Squared bought 13,093 Heron Therapeutics shares in Q2 2026, an estimated $10.5K.
  • Heron Therapeutics made up 0.01% of R Squared's portfolio in Q2 2026, its #491 holding.
  • R Squared first reported a position in Heron Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • R Squared's Heron Therapeutics position peaked at $26.9K in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.